StoneX Group’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

StoneX Group’s Portfolio CNCR Stock Details CNCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-16,565	Closed	-$350K	–	258
2019 Q2	$350K	Sell	16,565 -518	-3%	-$10.7K	0.22%	144
2019 Q1	$359K	Sell	17,083 -305	-2%	-$6.4K	0.27%	128
2018 Q4	$328K	Sell	17,388 -700	-4%	-$14.6K	0.32%	116
2018 Q3	$449K	Buy	18,088 +463	+3%	+$11.4K	0.33%	99
2018 Q2	$425K	Buy	17,625 +810	+5%	+$21.8K	0.37%	99
2018 Q1	$488K	Buy	16,815 +2,002	+14%	+$56.8K	0.47%	70
2017 Q4	$352K	Buy	14,813 +2,286	+18%	+$57.8K	0.37%	104
2017 Q3	$339K	Buy	12,527 +638	+5%	+$15.5K	0.42%	98
2017 Q2	$274K	Buy	+11,889	New	+$269K	0.09%	302

Other funds holding CNCR

BCWM LLC Overland Park, Kansas $353M AUM 20.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

SWM

SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return

APA

American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

StoneX Group's CNCR Position: Q3 2019 in Review

StoneX Group sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q3 2019, closing a stake of 16,565 shares — an estimated $350K sold.

StoneX Group first reported a position in CNCR in Q2 2017 and held it in 9 quarters. The position peaked at $488K in Q1 2018. 22 funds tracked by Wall St. Rank hold CNCR as of Q3 2019.

StoneX Group reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q3 2019 after selling out during the quarter.
StoneX Group sold 16,565 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q3 2019, an estimated $350K.
StoneX Group first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q2 2017 and held it in 9 quarters.
StoneX Group's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $488K in Q1 2018.
22 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q3 2019.

Based on StoneX Group's 13F filing for Q3 2019, filed 12 Nov 2019.